

## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on March 2023

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
<b>2) New Requests</b>				
Fostamatinib	<b>RED</b>			As per NICE TA835
Modulen IBD			√	Deferred
Otigo® Phenazone and lidocaine ear drops for otitis media as per URT guidance	<b>AMB 1</b>			New guidance in Hull and ERY. Awaiting update to Northern Lincolnshire guidance
<b>3) New formulations &amp; extensions to use</b>				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>4) Products considered by NICE</b>				
<a href="#">TA856: Upadacitinib for treating moderately to severely active ulcerative colitis</a>	RED			
<a href="#">TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy</a>	RED			
<a href="#">TA857: Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma</a>	RED			
<a href="#">TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma</a>	RED			
<a href="#">TA860: Maribavir for treating refractory cytomegalovirus infection after transplant</a>	RED			
<b>5) Appeals against earlier decisions by the APC</b>				
None				
<b>6) Miscellaneous formulary decisions by the APC</b>				
Octreotide long acting (high output stoma)	AMB SCP			Only commissioned in Hull/ERY only currently
Methenamine Hipurate	AMB 1			On recommendation of appropriate specialist only e.g. urology/department of infection

The following guidelines were presented to and approved at the March 2023 meeting of the APC:

- Nil

## DECISION SUMMARY

The following Green+ drug information leaflets were presented to and approved at the March 2023 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the March 2023 meeting of the APC:

- Nil

Other documents presented to and approved at the March 2023 meeting of the APC:

- Nil